Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin aspart
Drug: insulin human

First Posted Date: 2011-01-04

Last Posted Date: 2014-06-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 13

Registration Number: NCT01269606

First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

Phase 1

Terminated

Conditions: Inflammation
Psoriasis

Interventions: Drug: placebo
Drug: anti-IL-20

First Posted Date: 2010-12-16

Last Posted Date: 2017-02-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 55

Registration Number: NCT01261767

Locations: 🇺🇸
Novo Nordisk Investigational Site, Norfolk, Virginia, United States

Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency

Phase 3

Completed

Conditions: Congenital FXIII Deficiency
Congenital Bleeding Disorder

Interventions: Drug: catridecacog

First Posted Date: 2010-12-03

Last Posted Date: 2016-06-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 6

Registration Number: NCT01253811

Locations: 🇺🇸
Novo Nordisk Clinical Trial Call Center, Columbus, Ohio, United States

Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents

Phase 4

Completed

Conditions: Chronic Renal Insufficiency
Delivery Systems
Growth Hormone Deficiency in Children
Small for Gestational Age
Turner Syndrome
Chronic Kidney Disease
Growth Hormone Disorder
Foetal Growth Problem
Genetic Disorder

Interventions: Device: Norditropin NordiFlex®

First Posted Date: 2010-11-22

Last Posted Date: 2017-02-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 103

Registration Number: NCT01245374

Locations: 🇫🇷
Novo Nordisk Investigational Site, Paris La défense cedex, France

Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: biphasic insulin aspart 50

First Posted Date: 2010-11-17

Last Posted Date: 2015-05-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01242826

A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543

Phase 1

Completed

Conditions: Haemophilia A
Congenital Bleeding Disorder

Interventions: Drug: turoctocog alfa

First Posted Date: 2010-11-10

Last Posted Date: 2017-02-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 6

Registration Number: NCT01238367

Locations: 🇯🇵
Novo Nordisk Investigational Site, Suginami-ku, Tokyo, Japan

Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia B
Haemophilia A

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2010-11-04

Last Posted Date: 2014-11-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 35

Registration Number: NCT01234545

Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Insulin detemir
Dietary Supplement: Dietary regimen

First Posted Date: 2010-11-02

Last Posted Date: 2017-05-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 611

Registration Number: NCT01232491

Locations: 🇹🇷
Novo Nordisk Investigational Site, Samsun, Turkey

Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency

Phase 3

Completed

Conditions: Congenital Bleeding Disorder
Congenital FXIII Deficiency

Interventions: Drug: catridecacog

First Posted Date: 2010-10-28

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 6

Registration Number: NCT01230021

Locations: 🇬🇧
Novo Nordisk Investigational Site, Reading, United Kingdom

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A
Haemophilia B
Healthy

Interventions: Drug: NNC 0172-0000-2021
Drug: placebo

First Posted Date: 2010-10-26

Last Posted Date: 2019-05-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 52

Registration Number: NCT01228669

Locations: 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy